CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12. Hykes already has familiarity with the Minneapolis-based neurostimulation technology developer, having joined its board in December 2022. He will continue to serve on the board, with CEO Nadim Yared set to retire from the company and resign […]
CVRx Inc.
CVRx stock dips despite Street-beating Q4
CVRx (Nasdaq:CVRX) shares took a hit today despite fourth-quarter results that beat the consensus forecast. Shares of CVRx fell 5.2% at $27.69 apiece in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Minneapolis-based neuromodulation technology developer posted losses of $9.2 million. […]
CVRx is one of the best performing stocks out of Minnesota
CVRx (Nasdaq:CVRX) reached near the top of a list of Minnesota S&P 500 companies with best-performing stocks. With a 71% return in 2023, CVRx was No. 4 among the Minnesota “Fantastic Four” stocks, according to an analysis in the Star Tribune of Minneapolis. For comparison, the S&P 500 was up 24%. The maker of the […]
FDA approves expanded label for CVRx neuromod tech
CVRx (Nasdaq:CVRX) announced today that it received FDA approval for revised instructions for use for its Barostim neuromodulation system. The new instructions for use incorporate key long-term data from the Minneapolis-based company’s BeAT-HF randomized clinical trial. CVRx designed Barostim to deliver electrical pulses to baroreceptors in the wall of the carotid artery. These activate the […]
CVRx scores Medicare win on outpatient Barostim payments
CVRx (Nasdaq:CVRX) announced today that the Centers for Medicare and Medicaid Services (CMS) reassigned its Barostim implant procedure. The CMS change assigns the CVRx neuromodulation implant for procedures performed in the outpatient setting. It comes as part of the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. Barostim’s reassignment brings it to New Technology […]
Study backs CVRx Barostim neuromod for patients with heart failure
Data presented today supported the use of the Barostim neuromodulation device from CVRx (Nasdaq:CVRX) in patients with cardiovascular diseases. The BeAT-HF trial evaluated the Barostim extravascular, implantable neuromodulation device. Dr. Michael Zile, professor of cardiology at the Medical University of South Carolina, presented findings at the second annual Technology and Heart Failure (HF) Therapeutics (THT) […]
CVRx nearly doubles its revenue in Q4
CVRx (NASDAQ: CVRX) reported Street-beating Q4 results amid increased adoption of its implantable neuromodulation system for treating heart failure symptoms. Minneapolis-based CVRx announced yesterday evening that it lost $10.5 million, or 51¢ per share, off of $7.2 million in revenue for the quarter that ended Dec. 31. 2022. Sales were up 96% compared with the […]
CVRx launches new Barostim programmer in U.S.
CVRx (Nasdaq:CVRX) announced that it launched its new Barostim programmer following its approval by the FDA earlier this year. Minneapolis-based CVRx designed its second-generation programmer to operate on an upgraded cellular network to enable remote view access. It also includes an improved user interface that simplifies implantable pulse generator (IPG) programming. According to a news […]
FDA approves magnetic resonance labeling for CVRx’s Barostim neuromodulation system
CVRx (Nasdaq:CVRX) announced today that the FDA approved magnetic resonance (MR) conditional labeling for its Barostim system. The Barostim neuromodulation system for treating the symptoms of heart failure now includes instructions to allow for safe MRI scans of the head and lower extremities, offering heart failure patients implanted with Barostim more diagnostic options. Minneapolis-based CVRx […]
CVRx rises on Street-beating Q3
CVRx (NSDQ:CVRX) shares ticked up today on third-quarter results that came in ahead of the consensus forecast. The Minneapolis-based implantable neuromodulation technology developer posted losses of $6.1 million, or 30¢ per share, on sales of $3.4 million for the three months ended Sept. 30, 2021, for a nearly doubled bottom-line slide deeper into the red […]
Medtech veteran Martha Shadan joins CVRx board of directors
CVRx today said that medtech veteran Martha Shadan has joined its board of directors. Shadan has more than 30 years of experience in the life sciences industry and has a long track record of success in commercializing medtech innovations in startups and large companies. She is currently the CEO of Miach Orthopedics. She has also […]